Drug Trial Radar · NCT00319566
Heart and Estrogen-Progestin Replacement Study (HERS)
Last checked: Nov 19, 2026Latest source record: Apr 27, 2006 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,430
Actual
Start
Jul 1992
Primary completion
Not stated
Study completion Jul 2001
Sponsor
- Lead sponsor
- University of California, San FranciscoAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Wyeth is now a wholly owned subsidiary of Pfizer
- First posted
- Apr 27, 2006
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- Double
- Primary purpose
- Prevention
- Who can join
- Female only, from 55 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to determine whether hormone replacement therapy in post menopausal women with coronary artery disease prevents future heart attacks or death from coronary heart disease.
Conditions
- Coronary Heart Disease
Interventions
Premarin .625 mg daily plus medroxyprogesterone 2.5 mg dailyDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Myocardial Infarction
- CHD Death
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of California San Francisco
San Francisco, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.